Treatment of hypermyoglobinemia after CRS plus HIPEC for patients with peritoneal carcinomatosis: A retrospective comparative study

被引:7
|
作者
Liu, Gang [1 ]
Ji, Zhong-He [1 ]
Yu, Yang [1 ]
Li, Xin-Bao [1 ]
Zhang, Yan-Bin [1 ]
Peng, Kai-Wen [1 ]
Li, Yan [1 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Peritoneal Canc Surg, 10 Tieyi Rd,Yangfangdian St, Beijing 100038, Peoples R China
关键词
cytoreductive surgery; hypermyoglobinemia; hyperthermic intraperitoneal chemotherapy; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; EPITHELIAL OVARIAN-CANCER; ACUTE KIDNEY INJURY; CYTOREDUCTIVE SURGERY; PSEUDOMYXOMA PERITONEI; COLORECTAL-CANCER; CHINESE CENTER; MYOGLOBIN; TRIAL;
D O I
10.1097/MD.0000000000008573
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This retrospective comparative study aims to explore the time courses of serum myoglobin (Mb) changes, and summarize our experience in treating patients with hypermyoglobinemia after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).This study covered 60 patients with peritoneal carcinomatosis treated with CRS + HIPEC as the study group, and another 25 cancer patients treated with conventional extensive surgery without HIPEC as the control group from February to October 2016. In the study group, patients with postoperative hypermyoglobinemia were on a comprehensive treatment regimen consisting intravenous injection of sodium bicarbonate solution according to the Mb level. In the control group, patients were recorded and treated with the same regimen except for special sodium bicarbonate solution. The preoperative and postoperative serum Mb, blood urine nitrogen (BUN), and creatinine (Cr) levels were evaluated.There were no significantly difference between the 2 groups in serum Mb, BUN, and Cr levels before surgery. Postoperative serum Mb levels were elevated in both groups and significantly higher on postoperative 0 to 2 days (P<.05) in the study group than the control group. The peak value of serum Mb levels (426.65108.386 g/L) occurred on the surgery day. The serum Mb change rate was much bigger in the study group than the control group. Serum BUN levels in both groups revealed a slow increase during the early postoperative period and were significantly lower in the study group than the control group on days 1 and 2. The serum Cr levels were similar and stable between the 2 groups after surgery. The serum Cr change rates changed synchronously with same tendency in both groups, and on postoperative day 1 the increase rate was bigger in the control group than the study group.Hypermyoglobinemia is a common and prominent lab abnormality after CRS + HIPEC, and serum Mb levels could be an early and sensitive indicator for dramatic disturbances in the internal milieu after CRS + HIPEC. Adequate treatment with sodium bicarbonate could accelerate the reduction in serum Mb levels and reduce the risk for major organ damages.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Role of CRS Plus HIPEC in Gastric Cancer Peritoneal Carcinomatosis
    Graziosi, Luigina
    Marino, Elisabetta
    Donini, Annibale
    JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (02) : 248 - 248
  • [2] Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS plus HIPEC for Peritoneal Surface Malignancy
    Somashekhar, S. P.
    Rohit, Kumar C.
    Ramya, Yethadka
    Zaveri, Shabber S.
    Ahuja, Vijay
    Namachivayam, Arun Kumar
    Ashwin, K. R.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (01) : 214 - 223
  • [3] Postoperative pain pathophysiology and treatment strategies after CRS plus HIPEC for peritoneal cancer
    Wang, Xiao
    Li, Tianzuo
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [4] Bidirectional intraperitoneal chemotherapy with oxaliplatin in the context of CRS and HIPEC in patients with peritoneal carcinomatosis
    Glockzin, G.
    Schlitt, H. J.
    Piso, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [5] Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
    Julia Kleber
    Jordi Yang Zhou
    Florian Weber
    Florian Bitterer
    Patricia Hauer
    Paul Kupke
    Katharina Kronenberg
    Edward K. Geissler
    Hans J. Schlitt
    Matthias Hornung
    James A. Hutchinson
    Jens M. Werner
    Cancer Immunology, Immunotherapy, 2023, 72 : 3867 - 3873
  • [6] Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
    Kleber, Julia
    Zhou, Jordi Yang
    Weber, Florian
    Bitterer, Florian
    Hauer, Patricia
    Kupke, Paul
    Kronenberg, Katharina
    Geissler, Edward K.
    Schlitt, Hans J.
    Hornung, Matthias
    Hutchinson, James A.
    Werner, Jens M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (11) : 3867 - 3873
  • [7] Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS+HIPEC for Peritoneal Surface Malignancy
    S. P. Somashekhar
    Kumar C. Rohit
    Yethadka Ramya
    Shabber S. Zaveri
    Vijay Ahuja
    Arun Kumar Namachivayam
    K. R. Ashwin
    Annals of Surgical Oncology, 2022, 29 : 214 - 223
  • [8] The Evolution of CRS and HIPEC for Ovarian Peritoneal Carcinomatosis in a Single Institution
    Skanthakumar, T.
    Tan, G.
    Teo, M.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S140 - S140
  • [9] Outcomes of Palliative CRS/HIPEC for Patients with Advanced Peritoneal Carcinomatosis from Appendiceal Cancer
    Hendrix, R. J.
    Corban, C.
    Cloyd, J. M.
    Ahmed, A.
    Johnston, F. M.
    Greer, J.
    Grotz, T. E.
    Leiting, J. L.
    Fournier, K. F.
    Lee, A. J.
    Dineen, S.
    Dessureault, S.
    Veerapong, J.
    Baumgartner, J.
    Clarke, C. N.
    Mogal, H.
    Staley, C. A.
    Zaidi, M. Y.
    Patel, S.
    Dhar, V.
    Abbott, D. E.
    Pokrzywa, C.
    Lafaro, K.
    Lee, B.
    Lambert, L.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S39 - S40
  • [10] CRS-HIPEC Prolongs Survival but is Not Curative for Patients with Peritoneal Carcinomatosis of Gastric Cancer
    T. Boerner
    A. Graichen
    T. Jeiter
    F. Zemann
    P. Renner
    L. März
    Y. Soeder
    H. J. Schlitt
    P. Piso
    M. H. Dahlke
    Annals of Surgical Oncology, 2016, 23 : 3972 - 3977